BriaCell Therapeutics Corp Warrant
BCTXW
BCTXW was delisted on the 26th of February, 2026.
4 hedge funds and large institutions have $197K invested in BriaCell Therapeutics Corp Warrant in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
63% more capital invested
Capital invested by funds: $121K → $197K (+$75.8K)
0.12% more ownership
Funds ownership: 2.88% → 3% (+0.12%)
0% more funds holding
Funds holding: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.17K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $154K | – | – | – |
|
|
RAM
2
Redmond Asset Management
Henrico,
Virginia
| $30.8K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $11.9K | +$4.17K | +19,035 | +190% |
|
4
Osaic Holdings
Scottsdale,
Arizona
| $328 | – | – | – |
|
BCTXW Hedge Fund Activity: Q3 2024 in Review
4 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q3 2024, worth a combined $197K — up 63% from $121K a quarter earlier.
Fund positioning in BCTXW was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $4.17K.
- 4 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $197K of BriaCell Therapeutics Corp Warrant stock for Q3 2024, up 63% quarter-over-quarter.
- 0 funds opened new BriaCell Therapeutics Corp Warrant positions in Q3 2024 and 0 closed out.
- The largest BriaCell Therapeutics Corp Warrant buyer in Q3 2024 was UBS Group, an estimated $4.17K added.
Based on aggregated 13F filings for Q3 2024.